Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-23T14:20:06.932Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment resistant schizophrenia – review and a call to action

Published online by Cambridge University Press:  27 November 2018

J. Lally Open the ORCID record for J. Lally [Opens in a new window]  and
F. Gaughran
J. Lally*
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK Department of Psychiatry, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Department of Psychiatry, School of Medicine and Medical Sciences, University College Dublin, St Vincent’s University Hospital, Dublin, Ireland Department of Psychiatry, St Vincent’s Hospital Fairview, Dublin, Ireland
F. Gaughran
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK National Psychosis Service, South London and Maudsley NHS Foundation Trust, London, UK
*
*Address for correspondence: Dr John Lally, PO63, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, De Crespigny Park, London SE5 8AF, UK. (Email: john.lally@kcl.ac.uk)
Get access Rights & Permissions [Opens in a new window]

Abstract

Recovery rates in schizophrenia remain suboptimal with up to one-third resistant to standard treatments, a population prevalence of 0.2%. Clozapine is the only evidenced-based treatment for treatment resistant schizophrenia (TRS), yet there are significant delays in its use or it may not be trialled, potentially impacting the chance of recovery. Better outcomes with earlier use of clozapine may be possible. There is emerging evidence that early treatment resistance is not uncommon from the earliest stages of psychosis. In this review, we provide an update on TRS, its epidemiology and its management, with a specific focus on the optimal use and timing of clozapine and augmentation strategies for the one-third of patients who do not respond to clozapine.

Keywords

Clozapineearly psychosismanagementrecoveryTRS
Type
Review Article
Information
Irish Journal of Psychological Medicine , Volume 36 , Issue 4: Psychosis: from early intervention to treatment resistance , December 2019 , pp. 279 - 291
Copyright
© College of Psychiatrists of Ireland 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agid, O, Arenovich, T, Sajeev, G, Zipursky, RB, Kapur, S, Foussias, G, Remington, G (2011). An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. Journal of Clinical Psychiatry 72, 1439–1444.CrossRefGoogle ScholarPubMed
Agid, O, Kapur, S, Arenovich, T, Zipursky, RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 60, 1228–1235.CrossRefGoogle ScholarPubMed
Antonio Pinto, SLP, Rosa, M, Domenico, G, Luigi, D (1999). Rehab rounds: cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. Psychiatric Services 50, 901–904.CrossRefGoogle Scholar
Bachmann, CJ, Aagaard, L, Bernardo, M, Brandt, L, Cartabia, M, Clavenna, A, Coma Fuste, A, Furu, K, Garuoliene, K, Hoffmann, F, Hollingworth, S, Huybrechts, KF, Kalverdijk, LJ, Kawakami, K, Kieler, H, Kinoshita, T, Lopez, SC, Machado-Alba, JE, Machado-Duque, ME, Mahesri, M, Nishtala, PS, Piovani, D, Reutfors, J, Saastamoinen, LK, Sato, I, Schuiling-Veninga, CCM, Shyu, YC, Siskind, D, Skurtveit, S, Verdoux, H, Wang, LJ, Zara Yahni, C, Zoega, H, Taylor, D (2017). International trends in clozapine use: a study in 17 countries. Acta Psychiatrica Scandinavica 136, 37–51.CrossRefGoogle ScholarPubMed
Barnes, TR, Leeson, VC, Paton, C, Marston, L, Davies, L, Whittaker, W, Osborn, D, Kumar, R, Keown, P, Zafar, R, Iqbal, K, Singh, V, Fridrich, P, Fitzgerald, Z, Bagalkote, H, Haddad, PM, Husni, M, Amos, T (2017). Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technology Assessment 21, 1–56.CrossRefGoogle ScholarPubMed
Barretto, EM, Kayo, M, Avrichir, BS, Sa, AR, Camargo, M, Napolitano, IC, Nery, FG, Pinto, JA Jr., Bannwart, S, Scemes, S, Di Sarno, E, Elkis, H (2009). A preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia. Journal of Nervous and Mental Disease 197, 865–868.CrossRefGoogle ScholarPubMed
Brunette, MF, Drake, RE, Xie, H, McHugo, GJ, Green, AI (2006). Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin 32, 637–643.CrossRefGoogle ScholarPubMed
Burns, A, Erickson, H, Brenner, C (2014). Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatric Services 65, 874–880.CrossRefGoogle ScholarPubMed
Carbon, M, Correll, CU (2014). Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues in Clinical Neuroscience 16, 505–524.Google Scholar
Chakos, M, Lieberman, J, Hoffman, E, Bradford, D, Sheitman, B (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158, 518–526.CrossRefGoogle ScholarPubMed
Chang, JS, Ahn, YM, Park, HJ, Lee, KY, Kim, SH, Kang, UG, Kim, YS (2008). Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 69, 720–731.CrossRefGoogle ScholarPubMed
Conley, RR, Kelly, DL, Richardson, CM, Tamminga, CA, Carpenter, WT Jr. (2003). The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. Journal of Clinical Psychopharmacology 23, 668–671.CrossRefGoogle ScholarPubMed
Correll, CU, Rubio, JM, Inczedy-Farkas, G, Birnbaum, ML, Kane, JM, Leucht, S (2017). Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74, 675–684.CrossRefGoogle ScholarPubMed
Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S (2009). Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 35, 443–457.CrossRefGoogle ScholarPubMed
Davis, MC, Fuller, MA, Strauss, ME, Konicki, PE, Jaskiw, GE (2014). Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatrica Scandinavica 130, 30–39.CrossRefGoogle ScholarPubMed
de Boer, J, Prikken, M, Lei, WU, Begemann, M, Sommer, I (2018). The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis. npj Schizophrenia 4, 1.CrossRefGoogle ScholarPubMed
Demjaha, A, Egerton, A, Murray, RM, Kapur, S, Howes, OD, Stone, JM, McGuire, PK (2014). Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biological Psychiatry 75, e11–e13.CrossRefGoogle ScholarPubMed
Demjaha, A, Lappin, JM, Stahl, D, Patel, MX, MacCabe, JH, Howes, OD, Heslin, M, Reininghaus, UA, Donoghue, K, Lomas, B, Charalambides, M, Onyejiaka, A, Fearon, P, Jones, P, Doody, G, Morgan, C, Dazzan, P, Murray, RM (2017). Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychological Medicine 47, 1981–1989.CrossRefGoogle ScholarPubMed
Demjaha, A, Murray, RM, McGuire, PK, Kapur, S, Howes, OD (2012). Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. American Journal of Psychiatry 169, 1203–1210.CrossRefGoogle ScholarPubMed
Downs, J, Zinkler, M (2007). Clozapine: national review of postcode prescribing. The Psychiatrist 31, 384–387.Google Scholar
Doyle, R, Behan, C, O’Keeffe, D, Masterson, S, Kinsella, A, Kelly, A, Sheridan, A, Keating, D, Hynes, C, Madigan, K, Lawlor, E, Clarke, M (2017). Clozapine use in a cohort of first-episode psychosis. Journal of Clinical Psychopharmacol 37, 512–517.CrossRefGoogle Scholar
Elkis, H, Buckley, PF (2016). Treatment-resistant schizophrenia. Psychiatric Clinics of North America 39, 239–265.CrossRefGoogle ScholarPubMed
Fernandez-Egea, E, Worbe, Y, Bernardo, M, Robbins, TW (2018). Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. Psychological Medicine 19, 1–8.Google Scholar
Frogley, C, Taylor, D, Dickens, G, Picchioni, M (2012). A systematic review of the evidence of clozapine’s anti-aggressive effects. International Clinical Psychopharmacology 15, 1351–1371.Google ScholarPubMed
Galling, B, Roldan, A, Hagi, K, Rietschel, L, Walyzada, F, Zheng, W, Cao, XL, Xiang, YT, Zink, M, Kane, JM, Nielsen, J, Leucht, S, Correll, CU (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 16, 77–89.CrossRefGoogle ScholarPubMed
Galling, B, Vernon, JA, Pagsberg, AK, Wadhwa, A, Grudnikoff, E, Seidman, AJ, Tsoy-Podosenin, M, Poyurovsky, M, Kane, JM, Correll, CU (2018). Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatrica Scandinavica 137, 187–205.CrossRefGoogle ScholarPubMed
Gregory, A, Mallikarjun, P, Upthegrove, R (2017). Treatment of depression in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry 211, 198–204.CrossRefGoogle ScholarPubMed
Hayes, RD, Downs, J, Chang, CK, Jackson, RG, Shetty, H, Broadbent, M, Hotopf, M, Stewart, R (2015). The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophrenia Bulletin 41, 644–655.CrossRefGoogle ScholarPubMed
Horsdal, HT, Wimberley, T, Kohler-Forsberg, O, Baandrup, L, Gasse, C (2017). Association between global functioning at first schizophrenia diagnosis and treatment resistance. Early Intervention Psychiatry. Published online 8 December 2017. doi:10.1111/eip.12522.CrossRefGoogle Scholar
Howes, OD, McCutcheon, R, Agid, O, de Bartolomeis, A, van Beveren, NJ, Birnbaum, ML, Bloomfield, MA, Bressan, RA, Buchanan, RW, Carpenter, WT, Castle, DJ, Citrome, L, Daskalakis, ZJ, Davidson, M, Drake, RJ, Dursun, S, Ebdrup, BH, Elkis, H, Falkai, P, Fleischacker, WW, Gadelha, A, Gaughran, F, Glenthoj, BY, Graff-Guerrero, A, Hallak, JE, Honer, WG, Kennedy, J, Kinon, BJ, Lawrie, SM, Lee, J, Leweke, FM, MacCabe, JH, McNabb, CB, Meltzer, H, Moller, HJ, Nakajima, S, Pantelis, C, Reis Marques, T, Remington, G, Rossell, SL, Russell, BR, Siu, CO, Suzuki, T, Sommer, IE, Taylor, D, Thomas, N, Ucok, A, Umbricht, D, Walters, JT, Kane, J, Correll, CU (2017). Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. American Journal of Psychiatry 174, 216–229.CrossRefGoogle Scholar
Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. British Journal of Psychiatry 201, 481–485.CrossRefGoogle ScholarPubMed
Itil, TM, Keskiner, A, Fink, M (1966). Therapeutic studies in “therapy resistant” schizophrenic patients. Comprehensive Psychiatry 7, 488–493.CrossRefGoogle ScholarPubMed
Iwata, Y, Nakajima, S, Plitman, E, Caravaggio, F, Kim, J, Shah, P, Mar, W, Chavez, S, De Luca, V, Mimura, M, Remington, G, Gerretsen, P, Graff-Guerrero, A (2018). Glutamatergic neurometabolite levels in patients with ultra treatment-resistant schizophrenia: a cross-sectional 3T Proton MRS study. Biological Psychiatry. Published online 26 September 2018. doi:10.1016/j.biopsych.2018.09.009.CrossRefGoogle Scholar
Jaaskelainen, E, Juola, P, Hirvonen, N, McGrath, JJ, Saha, S, Isohanni, M, Veijola, J, Miettunen, J (2013). A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin 39, 1296–1306.CrossRefGoogle Scholar
Jauhar, S, McKenna, PJ, Radua, J, Fung, E, Salvador, R, Laws, KR (2014). Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. British Journal of Psychiatry 204, 20–29.CrossRefGoogle ScholarPubMed
Kahn, RS, Winter van Rossum, I, Leucht, S, McGuire, P, Lewis, SW, Leboyer, M, Arango, C, Dazzan, P, Drake, R, Heres, S, Díaz-Caneja, CM, Rujescu, D, Weiser, M, Galderisi, S, Glenthøj, B, Eijkemans, MJC, Fleischhacker, WW, Kapur, S, Sommer, IE, Kahn, RS, Sommer, IE, Winter-van Rossum, I, Somers, M, Ywema, PC, Kapur, S, McGuire, P, Leboyer, M, Meyer-Lindenberg, A, Lewis, SW, Leucht, S, Arango, C, Fleischhacker, WW, Meijering, AL, Petter, J, Van de Brug, R, Schotsman, J, Zwerver, J, Peuskens, J, De Hert, M, Thys, E, Hranov, LG, Hranov, V, Libiger, J, Köhler, R, Mohr, P, Glenthoj, B, Broberg, B, Düring, S, Baandrup, L, Jamain, S, Heres, S, Rujescu, D, Giegling, I, Weiser, M, Bar Heim, M, Davidson, M, Galderisi, S, Bucci, P, Mucci, A, Rybakowski, J, Remlinger-Molenda, A, Gonen, I, Radu, P, Díaz-Marsá, M, Rodriguez, A, Palomo, T, Rodriguez-Jimenez, R, García-Portilla, P, Bernardo, M, Bobes, J, Vilares Oliveira, C, Berger, G, Wildt, C, Dazzan, P, Perez-Iglesias, R, Drake, R, Gregory, S, Wilson, D, Díaz-Caneja, CM, Eijkemans, MJC (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. The Lancet Psychiatry. Published online 13 August 2018. doi: 10.1016/S2215-0366(18)30252-9.CrossRefGoogle Scholar
Kane, J, Honigfeld, G, Singer, J, Meltzer, H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789–796.CrossRefGoogle ScholarPubMed
Kennedy, JL, Altar, CA, Taylor, DL, Degtiar, I, Hornberger, JC (2014). The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. International Clinical Psychopharmacology 29, 63–76.CrossRefGoogle ScholarPubMed
Kirwan, P, O’Connor, L, Sharma, K, McDonald, C (2017). The impact of switching to clozapine on psychiatric hospital admissions: a mirror-image study. Irish Journal of Psychological Medicine 1–5.CrossRefGoogle Scholar
Kohler-Forsberg, O, Horsdal, HT, Legge, SE, MacCabe, JH, Gasse, C (2017). Predictors of nonhospitalization and functional response in clozapine treatment: a nationwide, population-based cohort study. Journal of Clinical Psychopharmacology 37, 148–154.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63, 622–629.CrossRefGoogle ScholarPubMed
Kulkarni, J, Gavrilidis, E, Gwini, SM, Worsley, R, Grigg, J, Warren, A, Gurvich, C, Gilbert, H, Berk, M, Davis, SR (2016). Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry 73, 947–954.CrossRefGoogle ScholarPubMed
Kulkarni, J, Gavrilidis, E, Wang, W, Worsley, R, Fitzgerald, PB, Gurvich, C, Van Rheenen, T, Berk, M, Burger, H (2015). Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Molecular Psychiatry 20, 695–702.CrossRefGoogle ScholarPubMed
Kumra, S, Kranzler, H, Gerbino-Rosen, G, Kester, HM, DeThomas, C, Kafantaris, V, Correll, CU, Kane, JM (2008). Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological Psychiatry 63, 524–529.CrossRefGoogle ScholarPubMed
Lally, J, Ajnakina, O, Di Forti, M, Trotta, A, Demjaha, A, Kolliakou, A, Mondelli, V, Reis Marques, T, Pariante, C, Dazzan, P, Shergil, SS, Howes, OD, David, AS, MacCabe, JH, Gaughran, F, Murray, RM (2016a). Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine 46, 3231–3240.CrossRefGoogle ScholarPubMed
Lally, J, Ajnakina, O, Stubbs, B, Cullinane, M, Murphy, KC, Gaughran, F, Murray, RM (2017a). Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. British Journal of Psychiatry 211, 350–358.CrossRefGoogle ScholarPubMed
Lally, J, Al Kalbani, H, Krivoy, A, Murphy, KC, Gaughran, F, MacCabe, JH (2018). Hepatitis, interstitial nephritis, and pancreatitis in association with clozapine treatment: a systematic review of case series and reports. Journal of Clinical Psychopharmacology 38, 520–527.CrossRefGoogle ScholarPubMed
Lally, J, Gaughran, F, Timms, P, Curran, SR (2016b). Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmgenomics and Personalized Medicine 9, 117–129.CrossRefGoogle ScholarPubMed
Lally, J, Malik, S, Krivoy, A, Whiskey, E, Taylor, DM, Gaughran, FP, Flanagan, RJ, Mijovic, A, MacCabe, JH (2017b). The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review. Journal of Clinical Psychopharmacology 37, 600–604.CrossRefGoogle ScholarPubMed
Lally, J, Tully, J, Robertson, D, Stubbs, B, Gaughran, F, MacCabe, JH (2016c). Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 171, 215–224.CrossRefGoogle ScholarPubMed
Leucht, S, Helfer, B, Dold, M, Kissling, W, McGrath, JJ (2015a). Lithium for schizophrenia. Cochrane Database of Systematic Reviews, Cd003834.CrossRefGoogle Scholar
Leucht, S, Samara, M, Heres, S, Davis, JM (2016). Dose equivalents for antipsychotic drugs: the DDD method. Schizophrenia Bulletin 42 (Suppl 1): S90–S94.CrossRefGoogle ScholarPubMed
Leucht, S, Samara, M, Heres, S, Patel, MX, Furukawa, T, Cipriani, A, Geddes, J, Davis, JM (2015b). Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophrenia Bulletin 41, 1397–1402.CrossRefGoogle ScholarPubMed
Lokshin, P, Lerner, V, Miodownik, C, Dobrusin, M, Belmaker, RH (1999). Parenteral clozapine: five years of experience. Journal of Clinical Psychopharmacology 19, 479–480.CrossRefGoogle Scholar
Manu, P, Sarpal, D, Muir, O, Kane, JM, Correll, CU (2012). When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophrenia Research 134, 180–186.CrossRefGoogle ScholarPubMed
McCutcheon, R, Beck, K, Bloomfield, MA, Marques, TR, Rogdaki, M, Howes, OD (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. Journal of Psychopharmacology 29, 892–897.CrossRefGoogle ScholarPubMed
McCutcheon, R, Beck, K, D’Ambrosio, E, Donocik, J, Gobjila, C, Jauhar, S, Kaar, S, Pillinger, T, Reis Marques, T, Rogdaki, M, Howes, OD (2018). Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatrica Scandinavica 137, 39–46.CrossRefGoogle Scholar
McGrath, J, Saha, S, Chant, D, Welham, J (2008). Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 30, 67–76.CrossRefGoogle Scholar
Meltzer, HY (1992). Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin 18, 515–542.CrossRefGoogle ScholarPubMed
Meltzer, HY, Alphs, L, Green, AI, Altamura, AC, Anand, R, Bertoldi, A, Bourgeois, M, Chouinard, G, Islam, MZ, Kane, J, Krishnan, R, Lindenmayer, JP, Potkin, S (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82–91.CrossRefGoogle Scholar
Meltzer, HY, Bobo, WV, Roy, A, Jayathilake, K, Chen, Y, Ertugrul, A, Anil Yagcioglu, AE, Small, JG (2008). A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry 69, 274–285.CrossRefGoogle ScholarPubMed
Melzer-Ribeiro, DL, Rigonatti, SP, Kayo, M, Avrichir, BS, Ribeiro, RB, Santos, BD, Fortes, M, Elkis, H (2017). Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT sham controlled trial. Archives of Clinical Psychiatry (São Paulo) 44, 45–50.CrossRefGoogle Scholar
Moreno-Kustner, B, Martin, C, Pastor, L (2018). Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One 13, e0195687.CrossRefGoogle ScholarPubMed
Morrison, AP, Pyle, M, Gumley, A, Schwannauer, M, Turkington, D, MacLennan, G, Norrie, J, Hudson, J, Bowe, SE, French, P, Byrne, R, Syrett, S, Dudley, R, McLeod, HJ, Griffiths, H, Barnes, TRE, Davies, L, Kingdon, D, Aydinlar, S, Courtley, J, Douglas-Bailey, M, Graves, E, Holden, N, Hutton, J, Hutton, P, Irving, S, Jackson, C, Lebert, T, Mander, H, McCartney, L, Munro-Clark, T, Murphy, EK, Spanswick, M, Steele, A, Tip, L, Tully, S (2018). Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. The Lancet Psychiatry 5, 633–643.CrossRefGoogle Scholar
Mouchlianitis, E, Bloomfield, MA, Law, V, Beck, K, Selvaraj, S, Rasquinha, N, Waldman, A, Turkheimer, FE, Egerton, A, Stone, J, Howes, OD (2016). Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophrenia Bulletin 42, 744–752.CrossRefGoogle ScholarPubMed
Muscatello, MR, Bruno, A, Pandolfo, G, Mico, U, Scimeca, G, Di Nardo, F, Santoro, V, Spina, E, Zoccali, RA (2011). Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophrenia Research 127, 93–99.CrossRefGoogle ScholarPubMed
Mustafa, FA, Burke, JG, Abukmeil, SS, Scanlon, JJ, Cox, M (2015). “Schizophrenia past clozapine”: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry 48, 11–14.Google ScholarPubMed
NICE (2014). Psychosis and Schizophrenia in Adults: Treatment and Management (Clinical Guideline 178). Royal College of Psychiatrists: London.Google Scholar
Nielsen, J, Correll, CU, Manu, P, Kane, JM (2013). Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? Journal of Clinical Psychiatry 74, 603–613.CrossRefGoogle ScholarPubMed
Nielsen, J, Dahm, M, Lublin, H, Taylor, D (2010). Psychiatrists’ attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology 24, 965–971.CrossRefGoogle ScholarPubMed
Nielsen, J, Nielsen, RE, Correll, CU (2012). Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. Journal of Clinical Psychopharmacology 32, 678–683.CrossRefGoogle ScholarPubMed
Nielsen, J, Young, C, Ifteni, P, Kishimoto, T, Xiang, YT, Schulte, PF, Correll, CU, Taylor, D (2016). Worldwide differences in regulations of clozapine use. CNS Drugs 30, 149–161.CrossRefGoogle ScholarPubMed
Pai, NB, Vella, SC (2012). Reason for clozapine cessation. Acta Psychiatrica Scandinavica 125, 39–44.CrossRefGoogle ScholarPubMed
Petrides, G, Malur, C, Braga, RJ, Bailine, SH, Schooler, NR, Malhotra, AK, Kane, JM, Sanghani, S, Goldberg, TE, John, M, Mendelowitz, A (2015). Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. American Journal of Psychiatry 172, 52–58.CrossRefGoogle ScholarPubMed
Pharoah, F, Mari, J, Rathbone, J, Wong, W (2010). Family intervention for schizophrenia. Cochrane Database of Systematic Reviews, Cd000088.CrossRefGoogle Scholar
Remington, G, Agid, O, Foussias, G, Ferguson, L, McDonald, K, Powell, V (2013). Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) 225, 505–518.CrossRefGoogle ScholarPubMed
Ringback Weitoft, G, Berglund, M, Lindstrom, EA, Nilsson, M, Salmi, P, Rosen, M (2014). Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study. Pharmacoepidemiology and Drug Safety 23, 290–298.CrossRefGoogle ScholarPubMed
Samanaite, R, Gillespie, A, Sendt, KV, McQueen, G, MacCabe, JH, Egerton, A (2018). Biological predictors of clozapine response: a systematic review. Frontiers in Psychiatry 9, 327.CrossRefGoogle ScholarPubMed
Schirmbeck, F, Zink, M (2012). Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Current Neuropharmacology 10, 88–95.CrossRefGoogle ScholarPubMed
Schulte, P (2003). What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clinical Pharmacokinetics 42, 607–618.CrossRefGoogle ScholarPubMed
Schulte, PFJ, Stienen, JJ, Bogers, J, Cohen, D, van Dijk, D, Lionarons, WH, Sanders, SS, Heck, AH (2007). Compulsory treatment with clozapine: a retrospective long-term cohort study. International Journal of Law and Psychiatry 30, 539–545.CrossRefGoogle ScholarPubMed
Shiloh, R, Zemishlany, Z, Aizenberg, D, Radwan, M, Schwartz, B, Dorfman-Etrog, P, Modai, I, Khaikin, M, Weizman, A (1997). Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. British Journal of Psychiatry 171, 569–573.CrossRefGoogle ScholarPubMed
Siskind, D, Siskind, V, Kisely, S (2017). Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Canadian Journal of Psychiatry 62, 772–777.CrossRefGoogle ScholarPubMed
Siskind, DJ, Lee, M, Ravindran, A, Zhang, Q, Ma, E, Motamarri, B, Kisely, S (2018). Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Australian and New Zealand Journal of Psychiatry 52, 751–767.CrossRefGoogle ScholarPubMed
Sommer, IE, Begemann, MJ, Temmerman, A, Leucht, S (2012). Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin 38, 1003–1011.CrossRefGoogle ScholarPubMed
Srisurapanont, M, Suttajit, S, Maneeton, N, Maneeton, B (2015). Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. Journal of Psychiatric Research 62, 38–47.CrossRefGoogle ScholarPubMed
Stroup, TS, Gerhard, T, Crystal, S, Huang, C, Olfson, M (2014). Geographic and clinical variation in clozapine use in the United States. Psychiatric Services 65, 186–192.CrossRefGoogle ScholarPubMed
Stroup, TS, Gerhard, T, Crystal, S, Huang, C, Olfson, M (2016). Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. American Journal of Psychiatry 173, 166–173.CrossRefGoogle ScholarPubMed
Swets, M, Dekker, J, van Emmerik-van Oortmerssen, K, Smid, GE, Smit, F, de Haan, L, Schoevers, RA (2014). The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. Schizophrenia Research 152, 458–468.CrossRefGoogle ScholarPubMed
Taipale, H, Mehtala, J, Tanskanen, A, Tiihonen, J (2017). Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia – a nationwide study with 20-year follow-up. Schizophrenia Bulletin 44, 1381–1387.Google Scholar
Taylor, DM, Barnes, TRE, Young, AH (2018). The Maudsley Prescribing Guidelines in Psychiatry. Wiley: UK.Google Scholar
Taylor, DM, Smith, L, Gee, SH, Nielsen, J (2012). Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatrica Scandinavica 125, 15–24.CrossRefGoogle ScholarPubMed
Taylor, DM, Young, C, Paton, C (2003). Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Journal of Clinical Psychiatry 64, 30–34.CrossRefGoogle ScholarPubMed
Tharyan, P, Adams, CE (2005). Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews CD000076.Google Scholar
Tiihonen, J, Haukka, J, Taylor, M, Haddad, PM, Patel, MX, Korhonen, P (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry 168, 603–609.CrossRefGoogle Scholar
Tiihonen, J, Lonnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A, Haukka, J (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620–627.CrossRefGoogle Scholar
Tiihonen, J, Mittendorfer-Rutz, E, Majak, M, Mehtala, J, Hoti, F, Jedenius, E, Enkusson, D, Leval, A, Sermon, J, Tanskanen, A, Taipale, H (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry 74, 686–693.CrossRefGoogle Scholar
Tollefson, GD, Birkett, MA, Kiesler, GM, Wood, AJ (2001). Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biological Psychiatry 49, 52–63.CrossRefGoogle ScholarPubMed
Ucok, A, Cikrikcili, U, Karabulut, S, Salaj, A, Ozturk, M, Tabak, O, Durak, R (2015). Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. International Clinical Psychopharmacology 30, 290–295.CrossRefGoogle ScholarPubMed
Verdoux, H, Quiles, C, Bachmann, CJ, Siskind, D (2018). Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophrenia Research. Published online 4 June 2018. doi:10.1016/j.schres.2018.05.046 CrossRefGoogle Scholar
Vermeulen, JM, van Rooijen, G, van de Kerkhof, MPJ, Sutterland, AL, Correll, CU, de Haan, L (2018). Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 Years. Schizophr Bull. Published online 25 April 2018. doi:10.1093/schbul/sby052.CrossRefGoogle Scholar
Weiser, M, Levi, L, Burshtein, S, Hagin, M, Matei, VP, Podea, D, Micluţia, I, Tiugan, A, Pacala, B, Grecu, IG, Noy, A, Zamora, D, Davis, JM (2017). Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: a randomized controlled trial. Journal of Clinical Psychiatry 78, e758–e765.CrossRefGoogle ScholarPubMed
Wheeler, AJ (2008). Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Annals of Pharmacotherapy 42, 852–860.CrossRefGoogle ScholarPubMed
Wimberley, T, MacCabe, JH, Laursen, TM, Sorensen, HJ, Astrup, A, Horsdal, HT, Gasse, C, Stovring, H (2017). Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. American Journal of Psychiatry 174, 990–998.CrossRefGoogle ScholarPubMed
Wimberley, T, Støvring, H, Sørensen, HJ, Horsdal, HT, MacCabe, JH, Gasse, C (2016). Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. The Lancet Psychiatry 3, 358–366.CrossRefGoogle ScholarPubMed
Yoshimura, B, Yada, Y, So, R, Takaki, M, Yamada, N (2017). The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychological Medicine 250, 65–70.Google ScholarPubMed
Zheng, W, Xiang, YT, Yang, XH, Xiang, YQ, de Leon, J (2017). Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry 78, e498–e505.CrossRefGoogle ScholarPubMed